NEW HAVEN, Conn. — October 1, 2026
Arvinas, Inc. announced that novel biomarker data from the Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease will be presented as late-breaking oral and poster presentations at the 2026 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Seoul, South Korea. The presentations are scheduled for October 7 and will include oculomotor and biomarker data from the ongoing clinical study.
ARV-102 Targets LRRK2 Through Protein Degradation
ARV-102 is an investigational, orally bioavailable PROTAC degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2). LRRK2 is a multifunctional protein implicated in Parkinson’s disease and progressive supranuclear palsy (PSP). Arvinas is developing ARV-102 using its targeted protein degradation platform, with the candidate designed to selectively degrade LRRK2 rather than simply inhibit its activity. The program has been evaluated in Phase 1 studies involving healthy volunteers and patients with Parkinson’s disease.
Phase 1 Program Generates Biomarker and Oculomotor Data
The upcoming MDS presentations will provide additional clinical information from the Phase 1 ARV-102 program. The late-breaking oral presentation, titled “Phase 1 Study of ARV-102, a PROTAC LRRK2 Degrader, in Parkinson’s Disease: Oculomotor and Biomarker Data,” is scheduled for October 7, with a corresponding e-poster presentation. The company said the data will focus on biomarker and oculomotor assessments generated during the clinical trial. The source announcement does not disclose the numerical results of these analyses ahead of the conference presentation.
Advertisement
Arvinas Advances Targeted Protein Degradation Pipeline
ARV-102 is part of Arvinas’ broader pipeline of investigational protein degraders targeting disease-associated proteins across oncology and neurological disorders. The company is also developing ARV-393 against BCL6 in relapsed/refractory non-Hodgkin lymphoma, ARV-027 against polyglutamine-expanded androgen receptor in spinal-bulbar muscular atrophy, and ARV-6723 against HPK1 in advanced solid tumors. Arvinas’ platform is based on PROTAC technology designed to harness the body’s natural protein disposal system to selectively degrade disease-causing proteins. The upcoming ARV-102 data presentation will provide additional clinical and biomarker information as the company continues evaluating targeted protein degradation approaches in neurodegenerative disease..
Source:Arvinas, press release
